INVESTOR DAY
June 10, 2019

ANNOVERA™
(segesterone acetate and ethinyl estradiol vaginal system)

Bijuva™
(estradiol and progesterone) capsules

Imvexxy®
(estradiol vaginal inserts)

TXMD
Nasdaq Listed
Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop and commercialize IMVEXXY®, ANNOVERA™, Bijuva™ and our hormone therapy drug candidates and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products or preclude the approval of our future drug candidates; the length, cost and uncertain results of future clinical trials; the ability of our licensees to commercialize and distribute our products; our reliance on third parties to conduct our manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock and the concentration of power in our stock ownership.

This non-promotional presentation is intended for investor audiences only.
WELCOME

Robert Finizio
Chief Executive Officer

ANNOVERA™
(segesterone acetate and ethinyl estradiol vaginal system)

BiJuva™
(estradiol and progesterone) capsules

Imvexxy®
(estradiol vaginal inserts)

TXMD
Nasdaq Listed
TXMD Investor Day Agenda

11:00-11:10 AM  OVERVIEW AND INTRODUCTIONS
   Welcome – Robert Finizio
   Introductions – Brian Bernick, M.D.

11:10-11:50 AM  KEY OPINION LEADERS – IMVEXXY, BIJUVA AND ANNOVERA
   IMVEXXY – Risa Kagan, M.D.
   BIJUVA – James Simon, M.D.
   ANNOVERA – James Liu, M.D.
   Portfolio View – Jay Cohen, M.D.

11:50-12:00 PM  Q&A PANEL

12:00-1:00 PM  PORTFOLIO COMMERCIAL LAUNCH STRATEGY
   IMVEXXY Launch Strategy & Performance Metrics – Dawn Halkuff
   BIJUVA Launch Strategy & Performance Metrics – Dawn Halkuff
   ANNOVERA Launch Strategy - Dawn Halkuff
   BIO-IGNITE Update - Dedra Lyden
   Compounding Pharmacist Perspective - Donnie Calhoun
   Compounding Pharmacist Perspective - Scott Mazza

1:00-1:10 PM  Q&A PANEL

1:10-1:40 PM  PAYER OVERVIEW
   Payer Environment – Robert Lahman
   Payer Update – Mike Steelman
   ANNOVERA – Ambrose Carrejo

1:40-2:15 PM  CLOSING – PORTFOLIO OF 3 PRODUCTS AND FINANCIAL GUIDANCE
   How strategy, plan and model come together – Mitch Krassan
   Financial Guidance - Rob Finizio

2:15-2:30 PM  Q&A PANEL
CLINICAL INTRODUCTION

Brian Bernick, M.D.
Co-founder and Director
Focused on lifespan of the patient and healthcare provider’s needs

- Innovative products, chronic conditions, large markets
- Single call point
- Products transition from one to the next through the various stages of life
  - contraception $\rightarrow$ prenatal vitamins $\rightarrow$ contraception $\rightarrow$ vasomotor symptoms $\rightarrow$ vulvar and vaginal atrophy
- Patient cost conscious portfolio
  - Products with patient out-of-pocket costs of $35 or less with copay programs
  - Possibility of no out-of-pocket costs for Annovera
Risa Kagan, MD, FACOG, CCD, NCMP

- Clinical Professor in the Department of OB/GYN and Reproductive Sciences at UCSF
- Gynecologist and Clinical Research with Sutter East Bay Medical Foundation
- Past Trustee of NAMS
- Leading expert in sexual medicine and menopause
- Lead author for the pivotal peer reviewed publications on female sexual disorders, menopause and bone health
- Principal investigator for over 100 clinical trials of sexual disorders, menopause and bone health
Women are Menopausal More Than One-third of Their Lives

Median age of menopause onset is 51 years

82 years is the median life expectancy of women today

Vulvar and Vaginal Atrophy (VVA) is a chronic and progressive condition and is unlikely to resolve without medical intervention

Symptoms of VVA may include:
- Dyspareunia (vaginal pain associated with sexual activity)
- Vaginal dryness
- Vaginal and/or vulvar irritation/itching/burning
- Bleeding with sexual activity
- Dysuria (pain when urinating)

The Scope of VVA in the US
64 Million Menopausal Women in the US

~1 in 2
or
~32M
menopausal women
have symptomatic VVA

...but ONLY
50%
(~16M) have
received treatment

7%
are Treated with
Prescription VVA
Therapy

That means
93%
are NOT Treated with
Prescription VVA Therapy

- 18% (~5.7M) are previous VVA therapy users who have discontinued
- 25% (~8M) are current/former Over-the-Counter (OTC) therapy users

IMVEXXY is “Redefining Relief”
A highly effective patient experience supported by strong clinical attributes

- Small, digitally inserted, vaginal softgel insert that dissolves completely
- Easy to use without the need for an applicator
- Mess-free administration
- Use any-time of day
- New lowest approved doses of estradiol 4 mcg and 10 mcg
- Efficacy demonstrated as early as 2 weeks (secondary endpoint) and maintained through week 12
- PK data - No increase in systemic hormone levels beyond the normal postmenopausal range*
- Mechanism of action and dosing that are familiar and comfortable
- No patient education required for dose preparation or applicators
- Dose packaging to optimize compliance and convenience

➔ High patient satisfaction resulting in high refill rates

*The clinical relevance of systemic absorption rates for vaginal estrogen therapies is not known.
James A. Simon, MD, CCD, NCMP, IF

- Clinical Professor Division of Reproductive Endocrinology and Infertility Department of The George Washington University School of Medicine Washington, D.C.
- President, International Society for the Study of Women’s Sexual Health (ISSWSH)
- Past President, The North American Menopause Society (NAMS)
- Leading expert in sexual medicine and menopause
- Lead author for the pivotal peer reviewed publications on female sexual disorders and menopause
- Over 400 publications
- Principal investigator for more than 350 clinical trials
Menopause Overview

Menopause represents the natural life-stage transition when women stop having periods as the production of estrogen and progesterone decreases

- May result in physical and emotional symptoms\(^1\)
  - Symptoms include vasomotor symptoms (hot flashes and night sweats), mood changes and vaginal dryness
  - Prolonged lack of estrogen can affect the bones and cardiovascular system
- Estrogen is given to reduce symptoms and other long-term conditions
  - Increased risk for endometrial hyperplasia/endometrial cancer if estrogen unopposed\(^2\)
- Progesterone is given to prevent thickening of the uterine wall when estrogen is used\(^2\)

Vasomotor symptoms are experienced by the majority of women during the menopausal transition\(^3\)

- As many as 74% of menopausal women\(^4\)
- Up to 88% of perimenopausal women\(^4\)

Vasomotor symptoms typically continue for 4 to 5 years following menopause and may last more than 10 years after final menstrual period in some women\(^5,6\)

References
BIJUVA Product Development Rationale

- 2002 Women’s Health Initiative (WHI) study showed that the long-term use of certain synthetic hormones (a combination of medroxyprogesterone acetate and conjugated equine estrogens) increased the risk of breast cancer, stroke, heart attack and blood clots
  - Prior to BIJUVA, all FDA-approved combination hormonal products contain a synthetic progestin and not a bio-identical progesterone
- After WHI, women and healthcare providers shifted to bio-identical hormone therapy as an alternative despite estradiol and progesterone combinations being unapproved drugs for use together
- Compounding filled the need for bio-identical hormone therapy
- All the major medical societies and the FDA discourage the prescribing of compounded hormones

➢ NEED FOR AN FDA-APPROVED COMBINATION BIO-IDENTICAL HORMONE THERAPY

1) Symphony Health Solutions PHAST Data powered by IDV; Annual 2015
## Current Hormone Therapy Options for Vasomotor Symptoms

After WHI (2002), a majority of women and clinicians shifted to bio-identical hormone therapy\(^1\).\(^2\)

### FDA-APPROVED

<table>
<thead>
<tr>
<th>Combination Synthetic Estrogens + Progestins*</th>
<th>Separate Bio-identical Estradiol &amp; Progesterone</th>
<th>NOT FDA-APPROVED</th>
</tr>
</thead>
<tbody>
<tr>
<td>~ 2.5 million total annual prescriptions(^1)</td>
<td>~ 3.9 million total annual prescriptions (each)(^2)</td>
<td>12 - 18 million total annual prescriptions(^3)</td>
</tr>
<tr>
<td>Prempro®, Activella®, Angeliq®, Femhrt®, Climara Pro®, Combipatch®</td>
<td>Oral or transdermal estradiol &amp; Prometrium®</td>
<td>Compounded estradiol + progesterone</td>
</tr>
<tr>
<td>FDA-approved</td>
<td>Not FDA-approved to be used together</td>
<td>Not FDA-approved</td>
</tr>
<tr>
<td>1 copay</td>
<td>2 copays</td>
<td>Often not covered by insurance</td>
</tr>
<tr>
<td>Insurance coverage</td>
<td>Insurance coverage</td>
<td>Almost 100% out of pocket</td>
</tr>
</tbody>
</table>

### NEED FOR AN FDA-APPROVED COMBINATION BIO-IDENTICAL HORMONE THERAPY

- 1) Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2018
- 2) Includes the following drugs: Activella®, FemHRT®, Angeliq®, Generic 17b + Progestins, Prempro®, Premphase®, Duavee®, Brisdelle®
- 3) Composite of Fisher, J. QuintilesIMS, White Paper: A Profile of the US Compounding Pharmacy Market, internal surveying of compounding pharmacies & NAMS publications

All trademarks are the property of their respective owners.
BIJUVA is indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause

**KEY CLINICAL ATTRIBUTES**

- First and only bio-identical combination of estradiol to reduce moderate to severe hot flashes combined with progesterone to help reduce the risk to the endometrium
- Strong efficacy and safety data
- Sustained steady state of estradiol
- No clinically meaningful changes in weight or blood pressure
- No clinically meaningful changes in coagulation or lipid parameters
- No clinically meaningful changes in mammograms
- Clinically meaningful improvements in quality of life and sleep disturbance data
- High desired amenorrhea rates (no bleeding)

**OTHER KEY ATTRIBUTES**

- Once-a-day single oral softgel capsule – only approved continuous combined progesterone product
- No peanut allergen (as in other FDA-approved progesterone products)
- One prescription, one copay
- BIJUVA is available in blister packages containing 30 capsules

References:
ANNOVERA™
(segesterone acetate and ethinyl estradiol vaginal system)

James Liu, MD
- President, North American Menopause Society (NAMS)
- Chairman, Department of Obstetrics and Gynecology, University Hospitals Health System, MacDonald Women’s Hospital, Cleveland, Ohio
- Chair, Department of Reproductive Biology, Case Western Reserve University
- Obstetrician-Gynecologist in Chief, University Hospitals Health System
- Leading expert in fertility, contraception, sexual medicine and menopause
- Lead author for over 114 pivotal peer reviewed publications on women’s health
- Principal investigator for multiple clinical trials including NIH Contraceptive Clinical Trials Network
- Holds five patents on vaginal drug delivery
ANNOVERA - 1-Year Vaginal System
Segesterone Acetate [Nestorone®]/Ethiny1 Estradiol

First and only patient-controlled, procedure-free, long-lasting, reversible birth control

- ANNOVERA approved on August 10, 2018
  - Segesterone acetate component of ANNOVERA classified as NCE with 5 year exclusivity
- Developed by the Population Council – creator of the best selling long-acting contraceptive products
  - ParaGard® and Mirena® IUDs; Norplant® and Jadelle® implants®
  - Motivation was for a long-acting product that doesn’t require a procedure for insertion or removal

All trademarks are the property of their respective owners.
U.S. Contraceptive Market

- Contraception is most notably used for family planning, but also to control symptoms associated with menstruation, endometriosis, fibroids, acne and perimenopause
- Nearly all women (99%) have used contraceptives at some point in their lives\(^1\)
- Long-acting methods of contraception (IUDs and Implants) are experiencing the greatest growth (CAGR 15.3% from 2012 to 2017), while daily oral contraceptive use has declined (CAGR -4.2% from 2012 to 2017)\(^2\)
- Yet, these long-acting methods are not offered routinely by a large segment of women’s health providers
  - According to research, only 56% of office-based obstetricians/gynecologists, family practitioners, and adolescent medicine specialists offered on-site IUDs; only 32% offered implants\(^3\)
    - ~45% of preventive care visits among reproductive-age women are made to family practitioners, nurse practitioners, or internists\(^3\)
  - Less than a quarter of family practitioners report providing any form of long-acting reversible contraception\(^4\)

**Women and healthcare providers want a long-lasting, reversible, patient controlled and procedure-free birth control**

---

2. QuintilesIMS MIDAS, QuintilesIMS Analysis, Company filings.
ANNOVERA Key Attributes

ACCESS ATTRIBUTES

- Market shift to long-acting
- Offer women a long-term birth control option without requiring a procedure for insertion and removal like IUDs or Implants
- Available to all prescribers – no special training, equipment, or inventory
- Acceptable for women who haven’t had a child (nulliparous) or are not in a monogamous relationship\(^1\)
- “Vaginal System” – the only product in a potential new category of contraception with potential for $0 co-pay
- Does not require refrigeration

\(^{1}\) Lohr, et al. Use of intrauterine devices in nulliparous women. Contraception 95 (2017); 529-537
ANNOVERA Key Attributes

**CLINICAL ATTRIBUTES**

- Only FDA-approved long-lasting reversible birth control that doesn’t require a procedure or repeat visit
  - Empowers women to be in control of their fertility and menstruation
  - ANNOVERA is the only user-directed single 12-month birth control product (used in repeated 4-week cycles for 13 cycles)
- Highly effective in preventing pregnancy when used as directed (97.3%)
- High patient satisfaction in clinical trials (phase 3 acceptability study of 905 women)\(^1\)
  - 89% overall satisfaction, adherence (94.3%) and continuation (78%)
- Softer and more pliable than NuvaRing®
- Only product with new novel progestin - segesterone acetate\(^2\)
  - No androgenic or glucocorticoid effects at contraceptive doses* 
- Low rates of discontinuation related to irregular bleeding (1.7%)

---


*Based on pharmacological studies in animals and in vitro receptor binding studies. All trademarks are the property of their respective owners.
ANNOVERA Patient Types

- Broad-based product – a single contraceptive product for most patient and prescriber types
- Supports patient preference
- Amenable to women of all reproductive ages and demographics
- Highly effective
- Self-administered, long-lasting product that is reversible
- Nulliparous women (never had a child before)
- Between children – birth spacing
- Women not in monogamous relationships
- Ideal for adolescents of reproductive age who don’t want to take a product everyday, but don’t want a procedure or nulliparous or non-monogamous
- College women – no need for monthly refills
- Women in the military – control fertility for 1 year
Jay Cohen, MD

- Medical Director of all Women’s Healthcare of West Broward, Clinical Research, and Discovery Clinical Research, divisions of Envision Women’s Healthcare
- Board certified OB/GYN at all Women’s Healthcare of West Broward, a division of Envision Women’s Healthcare
- Author for multiple peer reviewed publications on women’s health
- Past of Board Member with the William Little OB/GYN Society, American Cancer Society (Breast Task Force), West Broward Unit of the American Cancer Society
- Principal Investigator of over 110 clinical trials on women’s healthcare
What Impact of TXMD Portfolio has on Typical Practice

- TXMD portfolio is important when covers critical stages of a woman’s life cycle
  - Leads to trust with Women
  - Very much like Wyeth, Ortho, Warner Chilcott – market is wide open

- Women are more apt to discuss sexual health with their doctors today
  - Women are staying healthier and active longer
  - Often question products and safety more

- Modern products supported by strong clinical data that enable a provider to meet patient demands for bio-identical therapy

- Cost point is the most important
  - Consumer focused company
  - Menopause products have $35 commercial co-pay with card; ~$40 for preferred Medicare Part D co-pay
  - ANNOVERA potential for no-copay due to potential new method of contraceptive
Why Do IMVEXXY and BIJUVA Matter to Typical Clinicians

- Addresses the real life discussions between patients and physicians

- IMVEXXY is a unique product with the lowest approved dose
  - Key issue today systemic vs local estrogen

- BIJUVA is the only FDA-approved systemic therapy that is bio-identical, meets demand of patients
  - Do not need to compound
  - Can replace use of two separate FDA-approved products, which are not approved in combination and are not supported by endometrial safety data

- One co-pay per product – affordability is key and creates compliance
How Can ANNOVERA Change Things

- Only one visit to the doctor and pharmacy
- Addresses important reasons women discontinue daily and/or monthly contraceptives
  - Access, insurance coverage
  - Adverse events such as bleeding, weight gain, and nausea
- Long lasting ring (cyclical dosing for 13 cycles)
- State mandated coverage and potential 19th contraceptive method
COMMERCIAL UPDATE

Building a Premier Women’s Health Portfolio

Dawn Halkuff
Chief Commercial Officer
The Power of a Women’s Health Portfolio

Contraception

CONTRACEPTION/ FEMALE PLANNING - PERIMENOPAUSE

Vasomotor Symptoms

Dyspareunia (Vulvar & Vaginal Atrophy)

Reproductive Health

MENOPAUSE MANAGEMENT
The Power of A Women’s Health Portfolio

Even though there are over 400,000 total writers for these products\(^2\)

~25,000 targets we call on represent over 60% of market opportunity for each product\(^2\)

---

1) Symphony Health Integrated Dataverse.
2) IQVIA National Prescriber Level Data.
Launch Approach Developed to Shift Entrenched Behavior

- No new Estrogen product launched since 2000
- Affordability a challenge for patients while insurance builds
- Prescribers typically slow writing during this phase because of lack of access

- Open access approach only works for a product that delivers a good patient experience
- $ spent went toward copay program, removed barrier to HCP writing and less expensive than pushing early through DTC
- IMVEXXY cost does not change for patient as insurance builds

- Continuous unlocking of new levers as insurance adjudication normalizes
Launch Results Remain Strong and On-Track: Strategy is Working

Imvexxy TRx Launch Comparison

- IMVEXXY continues to grow both weekly average volume and daily average volume for May (31 day month) vs April (30 day month)
- Average daily volume for 31 days in May 2019 increased to ~1,200 from ~1,000 for the 30 days in April 2019

References:
1. Total prescription data is based on IQVIA prescriber level data plus additional unique patient data identified through utilization of our affordability program. This includes a one week estimation for the lag in reporting retail data, which can cause minor fluctuations in historical comparisons.
2. Osphena and Intrarosa data sourced from Symphony Health Integrated Dataverse.
3. Vagifem data sourced from IQVIA National Prescriber Level Data.
All trademarks are the property of their respective owners.
**Strong Patient Adherence = Women are Staying on IMVEXXY**

<table>
<thead>
<tr>
<th>Month Initial Prescription Filled</th>
<th>Average # Fills for those Patients</th>
<th>Maximum Allowable Fills Given the Month of Initial Fill</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2019</td>
<td>1 Fills</td>
<td>1 Fills</td>
</tr>
<tr>
<td>Apr 2019</td>
<td>1.8 Fills</td>
<td>2 Fills</td>
</tr>
<tr>
<td>Mar 2019</td>
<td>2.4 Fills</td>
<td>3 Fills</td>
</tr>
<tr>
<td>Feb 2019</td>
<td>3.0 Fills</td>
<td>4 Fills</td>
</tr>
<tr>
<td>Jan 2019</td>
<td>3.6 Fills</td>
<td>5 Fills</td>
</tr>
<tr>
<td>Dec 2018</td>
<td>4.0 Fills</td>
<td>6 Fills</td>
</tr>
<tr>
<td>Nov 2018</td>
<td>4.7 Fills</td>
<td>7 Fills</td>
</tr>
<tr>
<td>Oct 2018</td>
<td>5.0 Fills</td>
<td>8 Fills</td>
</tr>
<tr>
<td>Sep 2018</td>
<td>5.6 Fills</td>
<td>9 Fills</td>
</tr>
<tr>
<td>Aug 2018</td>
<td>7.0 Fills</td>
<td>10 Fills</td>
</tr>
</tbody>
</table>

1) Average number of fills per patient is the average number of fills per patient grouped by their initial month on therapy.
2) Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program.
3) Average number of fills for all patients is calculated as Total Rx / Total Patients.

Example of calculation: For patients who filled their initial prescription in November 2018, each of those patients averaged 4.7 fills from November 2018 through May 2019.

Average fills for all patients through May 31, 2019 = 3.34
61% aided awareness among prescribers

Growing number of high volume writers every month

Highest association with lowest approved dose vs. competitors

Highest score on ease of Use vs. other estrogen competitors: no applicator, high patient satisfaction, mess-free administration, easy to use packaging

IMVEXXY has ~7% market share of TRx for the month of May 2019

1) Claims used in promotion to support a positive patient experience
2) Symphony Health Integrated Dataverse.
The Next Lever to Unlock to Support IMVEXXY Growth is Consumer in Q3

Introducing: “No Interruptions”

Research Findings Demonstrate Strong Engagement*

Strong Communication
Calls out functional and emotional benefits

Relatable
And Aspirational

70% of women found the ad to be appealing, leading to strong desire to talk to HCP

Persuasive Call To Action aligned with the top reason Patients and HCPs discuss VVA “Impact to Relationship”

Media Plan Across Multiple Platforms

Print

SEO-SEM

Point of Care

Digital

Social

* Market research data on file (May 2019).
BIJUVA UPDATE
A Large Target Market For BIJUVA

Once payer coverage achieved, expand BIO-IGNITE partnerships to access the compounding channel

Launched April 17, 2019

Target FDA-approved separate bio-identical E&P pills segment

~3.9M TRx (each)1 I $836M2 TAM

12M – 18M TRx3 I $2.5B-3.8B2 TAM

1) Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2018
2) Based on WAC pricing of $214.50
3) Composite of Fisher, J. QuintilesIMS, White Paper: A Profile of the US Compounding Pharmacy Market, internal surveying of compounding pharmacies & NAMS publications
Launch Plan Mirrors IMVEXXY
Focused on Driving Early Behavior Change that Leads to Long Term Adoption

- $35 or less out-of-pocket cost*
- Addresses the cost and coverage concerns which are often barriers to early adoption
- “Keep Cool” Early Experience Program drives appropriate patient and prescriber education
- Positive early clinical experience has the potential to drive momentum

*For commercial patients

• Pay No More Than $35 from Day 1 of launch
Early BIJUVA Uptake Insights

- Opportunity to reinvigorate category given little to no promotion by competitor
- Initial focus on those prescribers writing 2-Pill regimen
  - ~10 targets per sales representatives at start
- Since launch, ~1,100 writers and ~2,000 scripts
- ~80+% are also IMVEXXY writers
ANNOVERA™
(segestosterone acetate and ethinyl estradiol vaginal system)
U.S. Contraceptive Market

$5B U.S. net sales\(^1\)

~ 90mm annual scripts to ~20 million women\(^2\)

**Short-Acting Contraceptives**

- Complete control but no long acting benefits

**Oral Market Size:**

55% of sales in 2017\(^1\)

**LARC Market Size:**

15.3% 2012 to 2017\(^1\)

**Annovera™**

- Long-acting benefits without a procedure and complete control over fertility and menstruation

**Long-Acting Contraceptives**

- Long-acting benefits but requires a procedure and does not offer complete control

Oral contraceptive’s continue to lose market share (CAGR -4.2% 2012 to 2017) to long acting methods\(^1\)

---

1. QuintilesIMS MIDAS, QuintilesIMS Analysis, Company filings.
2. Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2017
Prescribers and Consumers are Open to ANNOVERA

• High level of acceptance from prescribers with 89% of prescribers very or somewhat likely to prescribe\(^1\)

• Providers report that they would expect to use ANNOVERA for 18% of their patients using birth control\(^2\)

• 2 consumer segments accounting for almost 50% of the population have a high openness to ANNOVERA and openness to switching their current birth control product\(^3\)

• Features that resonate for both prescribers and patients around long-acting/long-lasting and “patient-controlled”\(^4\)

---

1) Internal Concept Evaluation, n=100 HCPs, SurveyGizmo, Nov, 2018
2) Annovera HCP Concept/Positioning Study, n=300 HCPs, Phoenix, June 2019
3) Women in their Reproductive Years Segmentation, n=1000, SMI Alcott/Brado, May, 2019
ANNOVERA Launch Approach

- **3Q 19**: Launch limited units to meet inbound demand
- **4Q 19**: Align initial sales focus where states mandate coverage while ACA decision is made
- **1Q20 - 3Q20**: Full launch with initial focus on OBGYN target overlap with Menopause Products. Early consumer focus given how influential women are in the choice of birth control.
BIO-IGNITE Introduction

Dedra Reiger Lyden
Vice President, Strategic Partnerships & Initiatives
Bio-Ignite = Innovative Collaborative Approach

Large, Untapped Market
- Over 3,000 physicians are currently writing high volumes of bio-identical hormones
- Over 700 pharmacies are currently dispensing high volumes of bio-identical hormones
  - With marketing reps
- HYBRID pharmacy model (filling FDA approved and compounded products)
- Changing commercial and regulatory dynamics ultimately driving change in this market
- Compounding channel opportunity is ignored by pharmaceutical companies
- We want to be where our competition is not

Regulatory Environment
- Drug Quality and Security Act
- Loss of Third-Party Reimbursement
- USP <800> – Hazardous Drugs
Goal to activate all current stakeholders involved in the Bio-identical Hormone Replacement Therapy (BHRT) community, ensuring that TherapeuticsMD’s portfolio has the best national access and uptake possible.
Pharmacy Targeting:

- Over 1,750 are high tier targets
  - These locations produce the highest volume of compounded bio-identical hormone replacement therapy (CBHRT) scripts

Program Stats:

- Live Accounts: 45
- States Reached: 31
- In Vetting Process: 89
- In Contracting Process: 117
- Unique CBHRT Prescribers Identified not in IMS: 4,459
  - 1,202 are identified as high-value CBHRT HCP’s targeted by KAM’s
Donnie Calhoun, BPharm, RPh.

- Licensed pharmacist in Alabama and owner of Calhoun Compounding Pharmacy in Anniston, Alabama
- Past President of the National Community Pharmacists Association, Past President of the Alabama Board of Pharmacy, Past Executive Director of the Specialty Sterile Pharmaceutical Society
- Has held many positions with the Alabama Pharmacy Association
- Former CEO/Executive Vice President for the American College of Apothecaries, CEO/Executive Vice President for the American College of Veterinary Pharmacists and CEO/Executive Vice President for the American College of Apothecaries Research and Education Foundation
- Elected to the Pharmacist Mutual Board of Directors in 2005
Scott Mazza PharmD, MS, R.Ph.

- Over 30 years of clinical pharmacy experience in a variety of practice settings
- Currently oversees the Therapeutic Interchange Program for Polaris Pharmacy Services
- Served as Pharmacy Manager for a regional specialty and compounding pharmacy specializing in oncology and women’s health compounding services
- Former National Director of Regulatory Compliance and Professional Practice for CVS Caremark
- Served on both national and state Medicaid Pharmacy & Therapeutics Committees and currently maintains 27 pharmacist licenses
The U.S. Pharmacopeial Convention (USP) has issued USP General Chapter <800> Hazardous Drug Handling in Healthcare Settings, describing practice and quality standards for handling hazardous drugs (HDs) to promote patient safety, worker safety, and environmental protection.

Key Points:
- To protect patients, personnel, and the environment from hazardous drug contamination
- Estradiol and progesterone are considered hazardous drugs
- Upgrades to be compliant are timely and costly
- OSHA has adopted the standards for enforcement

Community compounding pharmacies had hoped this would go away, but it did not.
- Deadline for compliance now very close
Partnership Types

Pharmacy Profiles
1. Will not be USP <800> Compliant
   • No longer plans to compound BHRT
     ✓ Bio-Ignite provides access to the greatest subset of BHRT patients and
       prescribing HCPs
2. Will be USP 800 Compliant
   • Will still be capable of compounding forms of BHRT
     ✓ Bio-Ignite provides another option for their location to fill all patient and
       prescriber needs (not just a compounding)

Pharmacy Size and Reach
• Single pharmacy location (with/without wholesaler purchasing requirements)
• Multi pharmacy location, multi state, not self-distributing model
• Self-distributing pharmacy, 10-100’s of pharmacy locations
What is the opportunity for IMVEXXY and BIJUVA and why

Headwinds
- Community Pharmacies that compound are going through a significant market shift
  - Loss of reimbursement for many areas for compounded drugs including hormones
  - Significant increase in cost and regulation associated with compounding hormones and other “hazardous” drugs (USP800)

Solutions
- Pharmacy can continue to provide BHRT through FDA-approved product without increasing costs
- Decrease patient out-of-pocket through patient support program
- Respond to patient and provider requests for commercially available BHRT product
- Expand the tool chest with FDA-approved products
- Encourage pharmacy engagement with the medical community and patient community
Why are Community Pharmacies Right for this Opportunity

- Compounding pharmacies offer a concierge experience with patients
  - Available 24/7 and offer cell phone contact
  - Pharmacy business model has changed significantly over the past few years and will continue to change
  - Lower reimbursement, increasing costs of compliance
  - Need to find innovative solutions

- Compounding pharmacies opportunities
  - Increased prescriber access/relationships with HCPs who are not listed as prescribers in IMS
  - Large female patient demographic
  - Separate sales force to promote pharmacy offerings
  - Meet patient demands for FDA-approved BHRT products
Hybrid Pharmacy Based Rx Model

- The “Hybrid” pharmacy- compounding, specialty care and traditional Rxs
- Compounders are local community pharmacy providers and have key relationships with physicians and other community based health care providers
- Engage regularly with the prescriber community
- Pharmacies with a large female demographic
- Patient-centric approach establishes patient trust with their pharmacist
- Offer services not available with other delivery systems, such as charge accounts, free delivery, consultation services, and a host of others
- Ability to readily obtain refills for their patients, perform prior authorizations and other insurance services for their patients
- Medication Therapy Management Approach
PAYER OVERVIEW

Bob Lahman
Ret. SR VP Optum Rx

Mike Steelman
TXMD Vice President, Market Access

Ambrose Carrejo
Ret. Pharmaceutical Contracting Lead
Kaiser Permanente

ANNOVERA™
(segesterone acetate and ethinyl estradiol vaginal system)

Bijuva™
(estradiol and progesterone) capsules

Imvexxy®
(estradiol vaginal inserts)
4 mg - 10 mg
2019 US Payer Environment is Rapidly Evolving

New Pricing Pressures

- Authorized generics and lower WAC strategies are impacting rebate guarantees
- Rebate and Admin Fee pass through (transparency) tightening profitability
- HHS Proposed Rule may reshape prescription drug prices
- FDA approves Novartis’ $2.1 million gene therapy – making it the world’s most expensive drug

Acquisitions

- Cigna
- Express Scripts
- CVS
- aetna
- Centene Corporation
- WellCare Health Plans

All trademarks are the property of their respective owners.
### Commercial Payer Update

- Commercial Average Non Preferred Copay is $59
- IMVEXXY co-pay card offering can bring this down to $35

#### Among Covered Workers With Prescription Drug Coverage, Average Copayments and Coinsurance, 2018

<table>
<thead>
<tr>
<th>Plans With Three or More Tiers</th>
<th>Average Copayment</th>
<th>Average Coinsurance</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Tier</td>
<td>$11</td>
<td>19%</td>
</tr>
<tr>
<td>Second Tier</td>
<td>$33</td>
<td>26%</td>
</tr>
<tr>
<td>Third Tier</td>
<td>$59</td>
<td>36%</td>
</tr>
<tr>
<td>Fourth Tier</td>
<td>$105</td>
<td>31%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Plans With Two Tiers</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>First Tier</td>
<td>$11</td>
<td>NSD</td>
</tr>
<tr>
<td>Second Tier</td>
<td>$31</td>
<td>28%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Plans With the Same Cost Sharing For All Covered Drugs</th>
<th>Average Copayment</th>
<th>Average Coinsurance</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Tier</td>
<td>NSD</td>
<td>20%</td>
</tr>
</tbody>
</table>

**Note:** Number of tiers refers to the number of tiers excluding those specifically for specialty drugs.

NSD: Not Sufficient Data

Medicare Part D Payer Update

Medicare Part D Median Preferred Copay is $40


### Table 4: Median Cost Sharing (Copayments or Coinsurance Rates) for all Medicare Part D Stand-alone Prescription Drug Plans and Top 10 PDPs with the Highest Enrollment, 2018 and 2019

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SilverScript Choice</td>
<td>$3</td>
<td>$14</td>
<td>$3</td>
<td>$13</td>
<td>$42</td>
<td>$14</td>
<td>$42</td>
<td>$13</td>
<td>$46</td>
<td>$14</td>
<td>$45</td>
<td>$13</td>
<td>$46</td>
<td>$14</td>
<td>$33</td>
<td>$14</td>
<td>$33</td>
<td>$14</td>
</tr>
<tr>
<td>AARP MedicareRx Preferred</td>
<td>$5</td>
<td>$12</td>
<td>$5</td>
<td>$10</td>
<td>$37</td>
<td>$12</td>
<td>$37</td>
<td>$10</td>
<td>$40</td>
<td>$12</td>
<td>$40</td>
<td>$10</td>
<td>$40</td>
<td>$12</td>
<td>$33</td>
<td>$12</td>
<td>$33</td>
<td>$12</td>
</tr>
<tr>
<td>Humana Walmart Rx</td>
<td>$1</td>
<td>$4</td>
<td>$1</td>
<td>$4</td>
<td>20%</td>
<td>$4</td>
<td>20%</td>
<td>$4</td>
<td>35%</td>
<td>$4</td>
<td>35%</td>
<td>$4</td>
<td>35%</td>
<td>$4</td>
<td>25%</td>
<td>$4</td>
<td>25%</td>
<td>$4</td>
</tr>
<tr>
<td>Humana Preferred Rx</td>
<td>$0</td>
<td>$1</td>
<td>$0</td>
<td>$1</td>
<td>20%</td>
<td>$0</td>
<td>20%</td>
<td>$1</td>
<td>35%</td>
<td>$0</td>
<td>35%</td>
<td>$1</td>
<td>35%</td>
<td>$0</td>
<td>25%</td>
<td>$0</td>
<td>25%</td>
<td>$0</td>
</tr>
<tr>
<td>AARP MedicareRx Saver Plus</td>
<td>$1</td>
<td>$3</td>
<td>$1</td>
<td>$3</td>
<td>25%</td>
<td>$3</td>
<td>25%</td>
<td>$1</td>
<td>33%</td>
<td>$3</td>
<td>33%</td>
<td>$1</td>
<td>33%</td>
<td>$3</td>
<td>25%</td>
<td>$3</td>
<td>25%</td>
<td>$3</td>
</tr>
<tr>
<td>Aetna Medicare Rx Saver</td>
<td>$1</td>
<td>$2</td>
<td>$1</td>
<td>$2</td>
<td>25%</td>
<td>$2</td>
<td>25%</td>
<td>$1</td>
<td>33%</td>
<td>$2</td>
<td>33%</td>
<td>$1</td>
<td>33%</td>
<td>$2</td>
<td>25%</td>
<td>$2</td>
<td>25%</td>
<td>$2</td>
</tr>
<tr>
<td>WellCare Classic</td>
<td>$0</td>
<td>$1</td>
<td>$0</td>
<td>$1</td>
<td>35%</td>
<td>$3</td>
<td>35%</td>
<td>$1</td>
<td>35%</td>
<td>$3</td>
<td>35%</td>
<td>$1</td>
<td>35%</td>
<td>$3</td>
<td>33%</td>
<td>$1</td>
<td>33%</td>
<td>$3</td>
</tr>
<tr>
<td>Humana Enhanced</td>
<td>$3</td>
<td>$7</td>
<td>$3</td>
<td>$7</td>
<td>42%</td>
<td>$4</td>
<td>42%</td>
<td>$3</td>
<td>38%</td>
<td>$4</td>
<td>38%</td>
<td>$3</td>
<td>38%</td>
<td>$4</td>
<td>25%</td>
<td>$3</td>
<td>25%</td>
<td>$4</td>
</tr>
<tr>
<td>AARP MedicareRx Walgreens</td>
<td>$0</td>
<td>$6</td>
<td>$0</td>
<td>$6</td>
<td>32%</td>
<td>$5</td>
<td>32%</td>
<td>$6</td>
<td>33%</td>
<td>$5</td>
<td>33%</td>
<td>$6</td>
<td>33%</td>
<td>$5</td>
<td>25%</td>
<td>$6</td>
<td>25%</td>
<td>$5</td>
</tr>
<tr>
<td>Aetna Medicare Rx Value Plus</td>
<td>$1</td>
<td>$2</td>
<td>$1</td>
<td>$2</td>
<td>$47</td>
<td>$2</td>
<td>$47</td>
<td>$1</td>
<td>$47</td>
<td>$2</td>
<td>$47</td>
<td>$1</td>
<td>$47</td>
<td>$2</td>
<td>$47</td>
<td>$1</td>
<td>$47</td>
<td>$2</td>
</tr>
</tbody>
</table>

NOTE: PDP is prescription drug plan. Estimates are weighted medians for those plans that vary cost sharing by region (weighted by September 2018 enrollment). *Approximately 77% of September 2018 enrollees are in plans with a preferred brand copay and 23% are in plans with a preferred brand coinsurance.

The Power of 3 in the Payer World

Expected widespread insurance coverage across the portfolio in 1st Half, 2020

- Establishes TXMD as key Women’s Health product leader
- Back negotiating with the same Women’s Health contacts at the payers
- Contract amendments in larger category with little Medicare Part D overall

**ANNOVERA™**
(segesterone acetate and ethinyl estradiol vaginal system)
- Establishes TXMD as a Women’s Health company with products across the life stages
- Back again with the same payer contacts
- Largest Women’s Health Category with no Medicare Part D
- ACA and State mandates exist in birth control category

**Bijuva™**
(estradiol and progesterone) capsules
- Establishes TXMD as key Women’s Health product leader
- Back negotiating with the same Women’s Health contacts at the payers
- Contract amendments in larger category with little Medicare Part D overall

**Imvexxy™**
(estradiol vaginal inserts) 1mg:2mg
- Introduced TXMD to the Women’s Health contacts in the payer community
- Started base contracts from scratch in Commercial and Medicare
- Smallest category of the portfolio with highest Medicare Part D patient population and longest time lag to access

**Target Timeline for Insurance Coverage from Launch**

- **Commercial**
  - 1-3 Quarters from launch.
  - ACA / 19th Category Designation decision by FDA will impact

- **Part D**
  - 3-4 Quarters Commercial
  - Part D not viewed as material at this point

- **4 Quarters Commercial**
- **6 Quarters for Part D**

---

Expected widespread insurance coverage across the portfolio in 1st Half, 2020
IMVEXXY Payer Update
~102M Commercial Lives are Unrestricted

Commercial Payer Update

- **Strategy:** Continue to seek unrestricted access in a fiscally responsible manner
- ~102 million lives are unrestricted with the majority being adjudicated at a Non Preferred copay*
- 21 states have greater than 60% unrestricted Commercial access
- IMVEXXY has secured access with the majority of the largest Commercial payers
- CVS and Aetna continue to not cover for the majority of their plan designs
  - Access available with a Non Preferred copay on open plan designs which is ~12% of CVS (~3.5M lives) and ~24% of Aetna (~1.8M lives)
  - Negotiations for all other plans with CVS / Aetna are ongoing seeking financially responsible opportunities to increase access

---

**Medicaid Cash**

- Medicaid: 5%
- Cash: 3%

**Commercial**

- Medicare Part D: 25%
- Commercial: 67%

---

1IMS Data April 2018
2Plan numbers as of May 2019 from MMIT
3MMIT May 2019 and Account Insights

*Adjudication of claim by payer: IMVEXXY is on payer formulary as covered product and is being submitted to insurance company for payment by payer to pharmacy.
Medicare Part D Update\(^1, 2\)

- **Strategy:** Continue to seek Preferred unrestricted access in a fiscally responsible manner
- IMVEXXY launched in July 2018, after the 2019 bid cycle was completed.
- ~12 million lives are unrestricted with a majority adjudicating at a Preferred copay (~$40)*
  - Pull through underway with key United Healthcare HCP targets
- 2020 bids submitted for other Medicare Part D plans
  - Plan to finalize these contracts in Q4, 2019 for adjudication in Q1, 2020

---

\(^1\)Plan numbers as of May 2019 from MMIT
\(^2\)MMIT May 2019 and Account Insights

*Adjudication of claim by payer: IMVEXXY is on payer formulary as covered product and is being submitted to insurance company for payment by payer to pharmacy.
BIJUVA Payer Update
~77M Commercial Lives are Unrestricted

Commercial Payer Update

- **Strategy:** Seek unrestricted access in a fiscally responsible manner
- BIJUVA clinical and financial reviews are underway with payers
- ~77 million Commercial lives are unrestricted with the majority adjudicating at a Non Preferred copay
- 2 of the top 10 already adjudicating*
- Most additional commercial plans will make a decision in Q3-Q4, 2019 with coverage the following quarter. Any plan we miss could take an additional 6-12 months to secure coverage

---

1IMIS Data April 2018
2Plan numbers as of May 2019 from MMIT
3MMIT May 2019 and Account Insights

*Adjudication of claim by payer: BIJUVA is on payer formulary as covered product and is being submitted to insurance company for payment by payer to pharmacy.
In 2012, the Affordable Care Act (ACA) required all health insurances to cover, without cost-sharing, the full range of contraceptive methods and services approved by the FDA as prescribed for women:
- 18 methods of birth control – at least one product in each method must be covered with no patient out-of-pocket costs
- If a provider recommends a specific option or product, plans must cover it at no cost as well
- Expectation that ANNOVERA would become the 19th method – 1-year contraceptive vaginal system

Irrespective of ACA mandate, 19 states require insurance plans to cover all contraceptives without a generic equivalent.
BIRTH CONTROL STATE LAWS REGARDLESS OF ACA MANDATES

10 STATES REQUIRE COVERAGE WITH NO COPAY REGARDLESS OF ACA DECISION
(~42 Million women in these states)

ANNOVERA™ (segesterone acetate and ethinyl estradiol vaginal system)

ANNOVERA coverage required with no co-pay

1 Data on file (May 2019).
2 Washington State Office of the Insurance Commissioner
9 STATES REQUIRE COVERAGE WITH COPAY REGARDLESS OF ACA DECISION
(~25 Million women in these states)

1 Data on file (May 2019).
Flat open, covered. There is one thing that scares the living hell out of me and it’s a female millennial with a smartphone and a Twitter and Facebook account. The last thing I want to do is set one of them off. The quickest way I could think of doing it would be to go out and mess with her birth control.

I can’t think of another category that we just leave broad open, don’t even think about…We’re mandated to cover it at zero co-pay…None of us was going to be the guy that said – oh, you can’t have your birth control. And so they’re just not managed.

The ACA mandate really drives a lot of the decision making within the process. And then pricing.

I think the point in the contraceptive class is to provide a number of different options for patients and providers.

1 Milliman Pricing Research on ANNOVERA May 2019
TXMD Power of the Portfolio

IMVEXXY® Revenue Drivers

- Launch full scale
- Limited Launch
- ANNOVERA™
  (segesterone acetate and ethinyl estradiol vaginal system)
- Launch in 10-19 states
- Expected widespread insurance coverage for all products
- Annual and high deductibles met
- Gain IMVEXXY commercial coverage, target HCPs with covered lives
- Additional Med D contracts secured
- Top 10 commercial payers decisions
- Q3/Q4 2019
- Q4 2019
- Q3/Q4 2019
- Q3/Q4 2019
- Q4 2019
- Q3/Q4 2019
- 1H 2020
- Q4 2019
- Q3 2019
- 1H 2020
- TXMD Power of the Portfolio

ANNOVERA™
(segesterone acetate and ethinyl estradiol vaginal system)
# IMVEXXY Model Different Than Typical Pharmaceutical Launch

## Gross Revenue

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Copay Assistance</td>
</tr>
<tr>
<td>Wholesale Costs</td>
</tr>
<tr>
<td>Pharmacy Discounts</td>
</tr>
<tr>
<td>Payer Rebates</td>
</tr>
<tr>
<td>Returns, Allowances &amp; Other Accruals</td>
</tr>
</tbody>
</table>

*Where We Focused*

## Net Revenue

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of Sales</td>
</tr>
</tbody>
</table>

## Gross Margin

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales &amp; Marketing Cost</td>
</tr>
</tbody>
</table>

*Copay Assistance substituted for Marketing Cost*
Example: Relationship of Cost of Copay Card vs Net Revenue Driven by Insurance Adjudication

- Relative Cost of Patient Affordability Programs
- Impact on Net Revenue from Payer Coverage
- Adjudication Rate

At Launch Normalization
**Example: How a Prescription is Paid & the Impact on Manufacturer**

<table>
<thead>
<tr>
<th></th>
<th>Column A</th>
<th>Column B</th>
<th>Column C</th>
<th>Column D</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient's Insurance</strong></td>
<td><strong>Commercial Insurance Used w/ Patient Deductible Not Yet Met &amp; High Deductible Plans</strong></td>
<td><strong>Commercial Insurance Used w/ Average Copay</strong></td>
<td><strong>Medicare Part D Insurance Used w/ Average Copay</strong></td>
<td></td>
</tr>
<tr>
<td>Doesn't Cover Product Yet</td>
<td>$200</td>
<td>$215</td>
<td>$40</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Payment from Copay Card</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(cost to Manufacturer)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Payment from Insurance Company</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Payment from Patient</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Amount Received by Pharmacy</strong></td>
<td>$235</td>
<td>$250</td>
<td>$250</td>
<td>$245</td>
</tr>
</tbody>
</table>

- For columns A and B, the copay card covers most of the cost of the product for the patient.
- For columns C and D, the insurance company pays most of the cost of the product for the patient.
## How Adjudication Rate Will Change Over Time: NOW

### Column A | Column B | Column C
--- | --- | ---
**IMVEXXY**
% of Business | 5% | 61% | 35%
% Adjudicated | 0% | 47% | 7%
Contribution to Overall Adjudication Rate | 0% | 29% | 2%
Overall Adjudication Rate | 31%

### Column A | Column B | Column C
--- | --- | ---
**BIJUVA**
% of Business | 8% | 82% | 9%
% Adjudicated | 0% | 30% | 0%
Contribution to Overall Adjudication Rate | 0% | 25% | 0%
Overall Adjudication Rate | 25%

*Chart are based on May Actuals*
## Target Adjudication Rate at Fully Established Insurance Coverage

<table>
<thead>
<tr>
<th>% of Business</th>
<th>% Adjudicated</th>
<th>Contribution to Overall Adjudication Rate</th>
<th>Overall Adjudication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMVEXXY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Column A</td>
<td>Column B</td>
<td>Column C</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No Insurance</td>
<td>Commercial Insurance</td>
<td>Medicare Eligible Patients</td>
</tr>
<tr>
<td>% of Business</td>
<td>8%</td>
<td>68%</td>
<td>24%</td>
</tr>
<tr>
<td>% Adjudicated</td>
<td>0%</td>
<td>75%</td>
<td>65%</td>
</tr>
<tr>
<td>Contribution to Overall Adjudication Rate</td>
<td>0%</td>
<td>51%</td>
<td>17%</td>
</tr>
<tr>
<td>Overall Adjudication Rate</td>
<td>68%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>% of Business</th>
<th>% Adjudicated</th>
<th>Contribution to Overall Adjudication Rate</th>
<th>Overall Adjudication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIJUVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Column A</td>
<td>Column B</td>
<td>Column C</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No Insurance</td>
<td>Commercial Insurance</td>
<td>Medicare Eligible Patients</td>
</tr>
<tr>
<td>% of Business</td>
<td>8%</td>
<td>82%</td>
<td>10%</td>
</tr>
<tr>
<td>% Adjudicated</td>
<td>0%</td>
<td>75%</td>
<td>65%</td>
</tr>
<tr>
<td>Contribution to Overall Adjudication Rate</td>
<td>0%</td>
<td>62%</td>
<td>7%</td>
</tr>
<tr>
<td>Overall Adjudication Rate</td>
<td>69%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Financial Update

Robert Finizio
Chief Executive Officer
$300M Non-Dilutive Term Loan Financing Secured

$200M accessed to date with up to additional $100M through Specific Company Milestones

<table>
<thead>
<tr>
<th>Tranche</th>
<th>Amount ($)</th>
<th>TXMD Company Milestone(^1)</th>
<th>Anticipated Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tranche 1</td>
<td>$200 million</td>
<td>Closing of the facility</td>
<td>Completed in April 2019</td>
</tr>
<tr>
<td>Tranche 2</td>
<td>$50 million</td>
<td>Designation of ANNOVERA as a new category of birth control by the U.S. Food and Drug Administration on or prior to December 31, 2019</td>
<td>Second Half of 2019</td>
</tr>
<tr>
<td>Tranche 3</td>
<td>$50 million</td>
<td>Achieving $11 million in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019</td>
<td>First Quarter of 2020</td>
</tr>
</tbody>
</table>

1. TXMD Company Milestones are draw triggers for additional tranches of funding only and are not affirmative covenants that the company must otherwise meet. Ability to draw additional tranches is also subject to satisfaction (or waiver) of other customary conditions precedent.
The Power of the Portfolio at Peak Sales $1B

### Percent of Market Based on Patient Count of 2.3M and 4 fills per year

<table>
<thead>
<tr>
<th>Average Net Revenue / Unit</th>
<th>20%</th>
<th>30%</th>
<th>40%</th>
<th>50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>$60</td>
<td>$110,400,000</td>
<td>$165,600,000</td>
<td>$220,800,000</td>
<td>$276,000,000</td>
</tr>
<tr>
<td>$80</td>
<td>$147,200,000</td>
<td>$220,800,000</td>
<td>$294,400,000</td>
<td>$368,000,000</td>
</tr>
<tr>
<td>$100</td>
<td>$184,000,000</td>
<td>$276,000,000</td>
<td>$368,000,000</td>
<td>$460,000,000</td>
</tr>
</tbody>
</table>

### Total Addressable FDA Market 3,800,000

### Total Addressable Compounding Market 12,000,000

### Percent of Addressable Market

<table>
<thead>
<tr>
<th>Average Net Revenue / Unit</th>
<th>20%</th>
<th>25%</th>
<th>35%</th>
<th>40%</th>
</tr>
</thead>
<tbody>
<tr>
<td>$60</td>
<td>$189,600,000</td>
<td>$237,000,000</td>
<td>$331,800,000</td>
<td>$379,200,000</td>
</tr>
<tr>
<td>$80</td>
<td>$252,800,000</td>
<td>$316,000,000</td>
<td>$442,400,000</td>
<td>$505,600,000</td>
</tr>
<tr>
<td>$100</td>
<td>$316,000,000</td>
<td>$395,000,000</td>
<td>$553,000,000</td>
<td>$632,000,000</td>
</tr>
</tbody>
</table>

### Addressable Birth Control Market NRx 28,000,000

### Addressable NuvaRing Market NRx 1,200,000

### Percent of Overall Market for Birth Control / Percent of NuvaRing Market of NRx

<table>
<thead>
<tr>
<th>Average Net Revenue / Unit</th>
<th>1.0% / 23%</th>
<th>1.5% / 35%</th>
<th>2.0% / 47%</th>
<th>2.5% / 58%</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,000</td>
<td>$280,000,000</td>
<td>$420,000,000</td>
<td>$560,000,000</td>
<td>$700,000,000</td>
</tr>
<tr>
<td>$1,500</td>
<td>$420,000,000</td>
<td>$630,000,000</td>
<td>$840,000,000</td>
<td>$1,050,000,000</td>
</tr>
<tr>
<td>$1,750</td>
<td>$490,000,000</td>
<td>$735,000,000</td>
<td>$980,000,000</td>
<td>$1,225,000,000</td>
</tr>
</tbody>
</table>
Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop and commercialize IMVEXXY®, ANNOVERA™, BIJUVA™ and our hormone therapy drug candidates and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products or preclude the approval of our future drug candidates; the length, cost and uncertain results of future clinical trials; the ability of our licensees to commercialize and distribute our products; our reliance on third parties to conduct our manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock and the concentration of power in our stock ownership.

This non-promotional presentation is intended for investor audiences only.
TXMD Financial Guidance Overview

FDA-Approved Drugs
Net Revenue

Prenatal Vitamins
Net Revenue
## 2019 TXMD Quarterly Financial Guidance

<table>
<thead>
<tr>
<th></th>
<th>1Q2019 Actual</th>
<th>2Q2019 Expectation</th>
<th>3Q2019 Expectation</th>
<th>4Q2019 Expectation</th>
<th>FY2019 Expectation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA-Approved Drugs</strong></td>
<td>$2.0M</td>
<td>$2.5-3.0M</td>
<td>$4.5-6.5M</td>
<td>$11-13M</td>
<td>$20-24.5M</td>
</tr>
<tr>
<td><strong>Prenatal Vitamins</strong></td>
<td>$1.9M</td>
<td>$2.0-2.5M</td>
<td>$1.75-2.25M</td>
<td>$1.5-2.0M</td>
<td>$7.15-8.65M</td>
</tr>
<tr>
<td><strong>Total TXMD</strong></td>
<td>$3.9M</td>
<td>$4.5-5.5M</td>
<td>$6.25-8.75M</td>
<td>$12.5-15M</td>
<td>$27.1-33.1M</td>
</tr>
</tbody>
</table>
## 2019 TXMD Annual Financial Guidance

<table>
<thead>
<tr>
<th></th>
<th>FY2018 Actual</th>
<th>FY2019 Expectation</th>
<th>y/y growth(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA-Approved Drugs</td>
<td>$1.0M</td>
<td>$20-24.5M</td>
<td>2,125%</td>
</tr>
<tr>
<td>Net Revenue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prenatal Vitamins</td>
<td>$15M</td>
<td>$7.15-8.65M</td>
<td>(47%)</td>
</tr>
<tr>
<td>Net Revenue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total TXMD</td>
<td>$16M</td>
<td>$27.1-33.1M</td>
<td>~88%</td>
</tr>
<tr>
<td>Net Revenue</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Important Guidance Notes:
- As our sales force focus shifts to our FDA-approved drugs and payer headwinds continue to increase for prenatal vitamins, we anticipate prenatal vitamins will continue to become a smaller percentage of overall company revenues.

---

1. y/y growth calculated at midpoint of guidance
Appendix
## Strong IMVEXXY Launch

### IMVEXXY Launch Metrics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total paid scripts dispensed to patients</td>
<td>~206,500</td>
</tr>
<tr>
<td>(since launch through May 31, 2019)</td>
<td></td>
</tr>
<tr>
<td>Total paid scripts</td>
<td>~37,700</td>
</tr>
<tr>
<td>(May 1-31, 2019)</td>
<td></td>
</tr>
<tr>
<td>Total patients</td>
<td>~61,800</td>
</tr>
<tr>
<td>(since launch through May 31, 2019)</td>
<td></td>
</tr>
<tr>
<td>Total prescribers</td>
<td>~12,000</td>
</tr>
<tr>
<td>(since launch through May 31, 2019)</td>
<td></td>
</tr>
</tbody>
</table>

### Comparison of Average Weekly & Daily Script Volume

(Average Weekly Volume: TRx for month / # days in month * 7 days)

<table>
<thead>
<tr>
<th>Metric</th>
<th>For 30 Days in Apr. 2019</th>
<th>For 31 Days in May. 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average weekly volume</td>
<td>~7,300</td>
<td>~8,500</td>
</tr>
<tr>
<td>Average daily volume</td>
<td>~1,040</td>
<td>~1,200</td>
</tr>
</tbody>
</table>

1 Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program. This includes a two week estimation for the lag in reporting retail data, which can cause minor fluctuations in historical comparisons.

2 Total Unique Prescribers that have sent a prescription to a pharmacy for at least 1 patient for IMVEXXY.
**Model To Change Behavior Is Working**

Scripts are accelerating while adjudication is increasing and adherence (staying on therapy) is growing

### IMVEXXY Launch Metrics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total paid scripts dispensed to patients¹ (since launch through May 31, 2019)</td>
<td>~206,500</td>
</tr>
<tr>
<td>Total paid scripts (May 1-31, 2019)</td>
<td>~37,700</td>
</tr>
<tr>
<td>Total patients (since launch through May 31, 2019)</td>
<td>~61,800</td>
</tr>
<tr>
<td>Total prescribers² (since launch through May 31, 2019)</td>
<td>~12,000</td>
</tr>
</tbody>
</table>

¹ Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program. This includes a one week estimation for the lag in reporting retail data, which can cause minor fluctuations in historical comparisons.

² Total Unique Prescribers that have sent a prescription to a pharmacy for at least 1 patient for IMVEXXY.
**IMVEXXY Product Characteristics Compare Favorably**

<table>
<thead>
<tr>
<th>Product</th>
<th>Estrogens</th>
<th>Non-estrogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrace® Cream (estradiol vaginal cream, USP, 0.01%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Premarin® (conjugated estrogens) Vaginal Cream&lt;sup&gt;2&lt;/sup&gt;</td>
<td>IMVEXXY® (estradiol vaginal inserts)&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>TRx MSB Dollars of Brand &amp; Generic 2018&lt;sup&gt;9&lt;/sup&gt;</td>
<td>$540,000,000</td>
<td>$462,226,000</td>
</tr>
<tr>
<td>2018 Total Units&lt;sup&gt;9&lt;/sup&gt;</td>
<td>1,902,000</td>
<td>1,220,000</td>
</tr>
<tr>
<td>Method of administration</td>
<td>Vaginal cream</td>
<td>Vaginal cream</td>
</tr>
<tr>
<td>Application</td>
<td>Reusable vaginal applicator-cream</td>
<td>Reusable vaginal applicator-cream</td>
</tr>
<tr>
<td>Active ingredient</td>
<td>100 mcg estradiol</td>
<td>625 mcg/g conjugated equine estrogens</td>
</tr>
<tr>
<td>Average maintenance dose</td>
<td>100 mcg 2x/week</td>
<td>312.5 mcg 2x/week</td>
</tr>
<tr>
<td>WAC package price (2018)&lt;sup&gt;10&lt;/sup&gt;</td>
<td>$314.87 (42.5-g tube)</td>
<td>$355.77 (30-g tube)</td>
</tr>
<tr>
<td>WAC 30-day supply (2018)&lt;sup&gt;10&lt;/sup&gt;</td>
<td>$104.96</td>
<td>$118.59</td>
</tr>
</tbody>
</table>

**Table References:**

8. Symphony Health Solutions PHAST Data powered by IDV; Annual 2018 and Imvexxy is 10 months data through May 2019.
9. 2017 Estrace and generics (Teva, Mylan, Impax & Alvogen) and 2017 Vagifem, Yuvafem (authorized generic of Vagifem), and Teva generic.

**Footnotes:**

There have been no head-to-head trials between IMVEXXY and any of the products listed above. All trademarks are the property of their respective owners. Abbreviations: WAC, wholesale acquisition cost.
**BIJUVA Launch Metrics**

<table>
<thead>
<tr>
<th>Metric</th>
<th>Metric Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total paid scripts dispensed to patients(^1) (since launch through May 31, 2019)</td>
<td>~2,000</td>
</tr>
<tr>
<td>Total paid scripts (May 1-31, 2019)</td>
<td>~1,600</td>
</tr>
<tr>
<td>Total patients (since launch through May 31, 2019)</td>
<td>~1,500</td>
</tr>
<tr>
<td>Total prescribers(^2) (since launch through May 31, 2019)</td>
<td>~1,100</td>
</tr>
</tbody>
</table>

\(^1\) Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program. This includes a two week estimation for the lag in reporting retail data, which can cause minor fluctuations in historical comparisons.

\(^2\) Total Unique Prescribers that have sent a prescription to a pharmacy for at least 1 patient for BIUVA.
# ANNOVERA Key Attributes

<table>
<thead>
<tr>
<th>Duration of Action</th>
<th>Oral Contraceptives</th>
<th>Vaginal Ring NuvaRing®</th>
<th>Contraceptive Injection</th>
<th>Vaginal System ANNOVERA™</th>
<th>IUDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily pill intake</td>
<td>1 month (21/7 regimen)</td>
<td>3 months</td>
<td>1 year (21/7 regimen)</td>
<td>3-10 years</td>
<td></td>
</tr>
<tr>
<td>Stop at any time</td>
<td>Removable at any time</td>
<td>Stop at any time, but residual effects for 3 months</td>
<td>Removable at any time</td>
<td>Procedure required</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Not universally acceptable</td>
</tr>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Not universally acceptable</td>
</tr>
</tbody>
</table>

| Nulliparous Women | Yes | Yes | Yes | Yes | Not universally acceptable |

<table>
<thead>
<tr>
<th>Product Administration</th>
<th>Oral intake</th>
<th>Patient administered flexible ring</th>
<th>Physician in-office injection every 3 months</th>
<th>Patient administered Soft and pliable vaginal system</th>
<th>Physician in-office procedure for insertion and removal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Convenience</td>
<td>Daily pill presents compliance and adherence risks; potential increase in unplanned pregnancies</td>
<td>Monthly pharmacy visit</td>
<td>Physician in-office injection, prescriber stocking required</td>
<td>1 doctor's visit, 1 pharmacy visit per year</td>
<td>Physician in-office procedure, prescriber stocking required</td>
</tr>
<tr>
<td>Healthcare Provider Convenience</td>
<td>Filled at pharmacy</td>
<td>Filled at pharmacy; Refrigeration required prior to being dispensed</td>
<td>Prescriber required to hold inventory</td>
<td>Filled at pharmacy; No refrigeration; No inventory or capital outlay</td>
<td>Prescriber required to hold inventory</td>
</tr>
<tr>
<td>Yearly WAC</td>
<td>Lo Loestrin® Fe: $1,829.36</td>
<td>NuvaRing® $2,114.19</td>
<td>Depo-Provera® $799.12</td>
<td>$1,800-$2,100</td>
<td>Liletta® $749.40 + $425.25 for insertion/removal Plus office visits and screenings</td>
</tr>
</tbody>
</table>

All trademarks are the property of their respective owners.
Top Contraceptive Products Based on Revenue

2018 Net Revenue (mm)

- **NUVARING**: $722
- **NEXPLANON IMPLANT**: $495
- **LO LOESTRIN FE BIRTH CONTROL PILL**: $528
- **MIRENA IUD FAMILY (INCLUDES MIRENA, KYLEENA & SKYLA)**: $750 (This includes 3)

Company filings; Net sales as reported in 2018 company filings.
Overview of TXMD’s Patents

- As of June 7, 2019, TherapeuticsMD’s patent portfolio includes:
  - 293 patent applications:
    - 24 issued U.S. patents
      - 12 U.S. patents have been listed in the Orange Book for BIJUVA
      - 3 U.S. patents have been listed in the Orange Book for IMVEXXY
    - 27 issued international patents
- TXMD currently has international patents or patent applications in:
  - Argentina
  - Australia
  - Brazil
  - Canada
  - China
  - Europe
  - Hong Kong
  - Israel
  - Japan
  - Mexico
  - New Zealand
  - Russia
  - South Africa
  - South Korea
## Overview of TXMD’s Patents for BIJUVA and IMVEXXY

<table>
<thead>
<tr>
<th>BIJUVA Patent Summary</th>
<th>IMVEXXY Patent Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Formulation and Method Claims</strong></td>
<td><strong>Formulation and Method Claims; Design Patent</strong></td>
</tr>
<tr>
<td>US Issued / Allowed</td>
<td>US Issued / Allowed</td>
</tr>
<tr>
<td>12* / 0</td>
<td>4 / 3</td>
</tr>
<tr>
<td>Expiration</td>
<td>Expiration</td>
</tr>
<tr>
<td>2032</td>
<td>No earlier than 2032</td>
</tr>
<tr>
<td>US Patents Pending</td>
<td>US Patents Pending</td>
</tr>
<tr>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>International Patents Granted</td>
<td>International Patents Granted</td>
</tr>
<tr>
<td>5</td>
<td>13</td>
</tr>
<tr>
<td>International Patents Pending</td>
<td>International Patents Pending</td>
</tr>
<tr>
<td>52</td>
<td>33</td>
</tr>
<tr>
<td>International Coverage</td>
<td>International Coverage</td>
</tr>
<tr>
<td>AR, AU, BR, CA, CN, EU, IL, MX, NZ, JP, KR, RU, ZA</td>
<td>AR, AU, BR, CA, EU, HK, IL, MX, NZ, JP, KR, RU, ZA</td>
</tr>
<tr>
<td>Expiration</td>
<td>Expiration</td>
</tr>
<tr>
<td>No earlier than 2032</td>
<td>No earlier than 2033</td>
</tr>
</tbody>
</table>

* This number does not include the 3 issued U.S. patents that cover the 0.25/50, 0.5/50, and 0.5/100 E+P dosage strengths